NEW YORK (dpa-AFX Broker) - US bank JPMorgan has upgraded Morphosys shares to "Overweight" with a price target of 31 euros following the detailed presentation of the Pelabresib trial data. The cancer drug was described by US hematologist Raajit Rampal as a potential paradigm shift in the treatment of myelofibrosis, analyst James Gordon wrote in his reaction on Monday morning. Overall, the study data support approval of the drug./ag/mis

Publication of the original study: 11.12.2023 / 07:24 / GMT

First disclosure of the original study: 11.12.2023 / 07:32 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------